Kazia Therapeutics to change ADS to Ordinary Share ratio
Ticker: KZIA · Form: 6-K · Filed: Apr 15, 2025 · CIK: 1075880
Sentiment: neutral
Topics: share-structure, ADS, ratio-change
TL;DR
Kazia's changing ADS ratio from 1:100 to 1:500 on April 29th - could affect share price.
AI Summary
Kazia Therapeutics Limited announced on April 15, 2025, a planned change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio will change from one ADS representing 100 Ordinary Shares to one ADS representing 500 Ordinary Shares. This adjustment is expected to take effect on April 29, 2025.
Why It Matters
This ratio change can impact the trading price and liquidity of the ADSs, potentially making them more accessible to a wider range of investors.
Risk Assessment
Risk Level: low — This is a routine administrative change related to share structure and does not indicate underlying business issues.
Key Numbers
- 1:100 — Old ADS to Ordinary Share Ratio (Current ratio before the change)
- 1:500 — New ADS to Ordinary Share Ratio (New ratio after the change)
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- American Depositary Shares (ADSs) (security) — Instrument affected by ratio change
- Ordinary Shares (security) — Underlying shares for ADSs
- April 29, 2025 (date) — Effective date of ratio change
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report a planned change in the ratio of Kazia Therapeutics Limited's American Depositary Shares (ADSs) to Ordinary Shares.
What is the current ratio of ADSs to Ordinary Shares?
The current ratio is one (1) ADS representing one hundred (100) Ordinary Shares.
What will be the new ratio of ADSs to Ordinary Shares?
The new ratio will be one (1) ADS representing five hundred (500) Ordinary Shares.
When is the ratio change expected to take effect?
The ratio change is expected to take effect on April 29, 2025.
What is the company's principal executive office address?
The principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 15, 2025 regarding KAZIA THERAPEUTICS LTD (KZIA).